Leandro Jonata Carvalho Oliveira, Medical Oncologist at Oncoclínicas Group, shared a post on LinkedIn: about a paper he co-authored with colleagues published in Springer Nature’s Breast Cancer Research and Treatment:
“Just out: our new article examining the evolving clinical utility of liquid biopsy for disease monitoring and guiding treatment switching in the 1L HR+, HER2- metastatic breast cancer setting, informed by key findings from PADA1 and SERENA6.
We review the historical development of blood-based biomarker–guided therapeutic adaptation and provide a comparative analysis of imaging- versus biomarker-guided treatment modification strategies in 1L HR+ mBC.
The review also highlights the main challenges in validating and implementing ctDNA-guided early endocrine switching in routine clinical practice, and discuss its potential to reshape monitoring and decision-making in this setting.
Grateful to my co-authors — Dr Max Mano, Dr Carlos Barrios, and Dr Rodrigo Dienstmann — for their invaluable collaboration.
Thank you as well, François-Clément Bidard, for leading this potential paradigm shift in mBC.”
Title: The promise of ctDNA-based, molecularly-driven early switch therapy from PADA-1 to SERENA-6
Authors: Leandro Jonata Carvalho Oliveira, Max Senna Mano, Carlos Barrios, Rodrigo Dienstmann
You can read the full article in Springer Nature.
More posts featuring Leandro Jonata Carvalho Oliveira.